Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 in Relapsed or Refractory High-Risk MDS or AML
NCT06268574Phase 2Terminated
- Sponsor
- Ryvu Therapeutics
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of rvu120 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Ryvu Therapeutics. Primary endpoint: Complete Remission at 12 months. Started Jan 2024; status: terminated.
02
Drugs
rvu120
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06268574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268574.